Praxis Precision Medicines (NASDAQ:PRAX) added ~134% in the premarket on Thursday after the Boston-based biotech announced that its experimental therapy ulixacaltamide succeeded in two late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback